Titan Pharmaceuticals Announces $1 Million Private Placement of Convertible Preferred Stock
April 11, 2025 16:15 ET | Source: Titan Pharmaceuticals, Inc. NEW YORK,…
NurExone Biologic Announces U.S. Uplisting Intention and Closes C$2.3 Million Private Placement
TORONTO and HAIFA, Israel, April 04, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic…
Woxsen University Releases MBA Placement Report 2025 showing Strong Growth in Industry Demand
HYDERABAD, India, April 1, 2025 /PRNewswire/ -- Woxsen University has released its…
Arch Biopartners Closes Non-Brokered Private Placement
TORONTO, March 14, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or…
ARCPOINT ANNOUNCES CLOSING OF NON-BROKERED PRIVATE PLACEMENT AND ANNOUNCES UPSIZE
For Immediate Release – Not for Dissemination in the United States or…
![Zelluna ASA [ZLNA]: The first ever cell therapy company to list on the Oslo Stock Exchange following successful completion of the business combination and private placement](https://i1.wp.com/ml-eu.globenewswire.com/media/MjU1NjVjOWEtMTBjOC00MTE0LWI0NTUtYjdlMjkzODM0MzYzLTEyMjA5NDY=/tiny/Zelluna-ASA.png?w=420&resize=420,280&ssl=1 "Zelluna ASA [ZLNA]: The first ever cell therapy company to list on the Oslo Stock Exchange following successful completion of the business combination and private placement")
Zelluna ASA [ZLNA]: The first ever cell therapy company to list on the Oslo Stock Exchange following successful completion of the business combination and private placement
March 03, 2025 10:46 ET | Source: Zelluna ASA Oslo, Norway, 03…
Carbeeza Inc. Announces Private Placement Financing
February 21, 2025 12:52 ET | Source: Carbeeza Inc. CALGARY, Alberta, Feb.…
Correction – Diagnos Announces Closing of Private Placement
In the original press release dated February 5, 2025, announcing the closing…
Dynamite Blockchain Announces Private Placement
The Company Seeks to Raise Capital to Develop its Kaspa Focused Strategy…
NEXTGEN DIGITAL ANNOUNCES UPSIZE OF NON-BROKERED PRIVATE PLACEMENT TO $1.2 MILLION & PURCHASE OF XRP COINS
– NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE…